ClinConnect ClinConnect Logo
Search / Trial NCT00314002

Catheter Thrombectomy in Patients With Massive Pulmonary Embolism

Launched by STRAUB MEDICAL AG · Apr 11, 2006

Trial Information

Current as of May 09, 2025

Terminated

Keywords

Massive Pulmonary Embolism Catheter Thrombectomy

ClinConnect Summary

Official Title: Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism

Principal Investigator: Nils Kucher, MD, Cardiovascular Division, Interventional Cardiology, Andreas Grüntzig Catheterization Laboratories, Raemistrasse 100 University Hospital Zurich, 8091 Zurich, Switzerland, Phone: +41 1 255 8762, kuchernils@yahoo.com

Sponsor: Straub Medical AG, Straubstrasse, 73 23 Wangs, Schweiz

August 29, 2005

I. BACKGROUND AND SIGNIFICANCE

A) Historical Background

Acute pulmonary embolism (PE) is a potentially life-threatening disease with an ove...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients \>= 18 years of age with pulmonary embolism and cardiogenic shock, defined as a systolic arterial pressure \<= 90 mmHg, a drop in systolic arterial pressure \>= 40 mmHg for \>= 15 minutes, or ongoing administration of catecholamines for systemic arterial hypotension
  • 2. Subtotal or total filling defect in the left and/or right main pulmonary artery due to massive PE, as assessed by chest computed tomography or by conventional pulmonary angiography
  • 3. Right ventricular dysfunction on echocardiography: RV systolic hypokinesis and/or RV dilation (optional)
  • 4. Failed thrombolysis or at least one of the following contraindications to PE thrombolysis present:
  • Active bleeding
  • History of intracranial bleeding
  • Surgery, delivery, organ biopsy, puncture of a non-compressible vessel within 10 days
  • History of stroke
  • Gastrointestinal bleeding within 10 days
  • Significant trauma within 15 days
  • Head injury requiring hospitalization within 1 year
  • Active cancer with known hemorrhagic risk
  • Neurosurgery or ophthalmologic surgery within the past year
  • Platelets \< 50,000 or INR \>2.0
  • Pregnancy
  • Exclusion Criteria
  • 1. Systemic (paradoxical) embolism in the presence of an atrial septal defect or patent foramen ovale
  • 2. Free floating right heart thrombi, left heart thrombi
  • 3. Life expectancy due to underlying disease less than one month

About Straub Medical Ag

Straub Medical AG is a pioneering medical device company dedicated to advancing cardiovascular health through innovative solutions. With a focus on the development and commercialization of cutting-edge technologies for the treatment of vascular diseases, Straub Medical AG combines rigorous research and clinical expertise to enhance patient outcomes. Committed to quality and safety, the company collaborates with healthcare professionals and institutions worldwide to deliver effective, minimally invasive treatment options. Its extensive portfolio reflects a strong commitment to improving healthcare standards and addressing unmet medical needs in the cardiovascular field.

Locations

Luzern, , Switzerland

Bad Neustadt, , Germany

Kiel, , Germany

Leipzig, , Germany

Magdeburg, , Germany

Patients applied

0 patients applied

Trial Officials

Nils Kucher, MD

Principal Investigator

Universitätsspital Zürich (USZ) Switzerland

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials